Clinical trial
Fulvestrant (FASLODEX™) as a Treatment in Postmenopausal Women With Estrogen…
NCT00093002 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00093002 |
|---|---|
| Title | Fulvestrant (FASLODEX™) as a Treatment in Postmenopausal Women With Estrogen Receptor Positive Breast Cancer |
| Official title | A Randomized, Open-Label, Multicenter, Phase II Study Comparing the Effects on Proliferation and the Efficacy and Tolerability of Fulvestrant (FASLODEX®) 500 mg With Fulvestrant (FASLODEX®) 250 mg When Given as Neoadjuvant Treatment in Postmenopausal Women With Estrogen Receptor Positive Breast… |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Fulvestrant |
| Enrollment | 179 |
| Start date | Jun 1, 2004 |
| Completion | Jul 1, 2007 |
| First posted | Sep 29, 2004 |
| Last update posted | Jun 12, 2008 |
| Countries | Austria, Brazil, Germany, India, United Kingdom, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: